ENTX
Price
$2.07
Change
+$0.06 (+2.99%)
Updated
Jun 6 closing price
Capitalization
91.36M
61 days until earnings call
STOK
Price
$11.14
Change
+$0.26 (+2.39%)
Updated
Jun 6 closing price
Capitalization
592.92M
64 days until earnings call
Interact to see
Advertisement

ENTX vs STOK

Header iconENTX vs STOK Comparison
Open Charts ENTX vs STOKBanner chart's image
Entera Bio
Price$2.07
Change+$0.06 (+2.99%)
Volume$34.32K
Capitalization91.36M
Stoke Therapeutics
Price$11.14
Change+$0.26 (+2.39%)
Volume$463.07K
Capitalization592.92M
ENTX vs STOK Comparison Chart
Loading...
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTX vs. STOK commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a Buy and STOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (ENTX: $1.84 vs. STOK: $9.43)
Brand notoriety: ENTX and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 123% vs. STOK: 57%
Market capitalization -- ENTX: $91.36M vs. STOK: $592.92M
ENTX [@Biotechnology] is valued at $91.36M. STOK’s [@Biotechnology] market capitalization is $592.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 0 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 0 green, 5 red.
According to our system of comparison, STOK is a better buy in the long-term than ENTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 4 bullish TA indicator(s).

  • ENTX’s TA Score: 5 bullish, 5 bearish.
  • STOK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ENTX and STOK are a good buy in the short-term.

Price Growth

ENTX (@Biotechnology) experienced а -3.93% price change this week, while STOK (@Biotechnology) price change was -0.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ENTX is expected to report earnings on Aug 08, 2025.

STOK is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($593M) has a higher market cap than ENTX($91.4M). ENTX YTD gains are higher at: -13.443 vs. STOK (-14.506). ENTX has higher annual earnings (EBITDA): -9.16M vs. STOK (-99.2M). STOK has more cash in the bank: 217M vs. ENTX (6.92M). ENTX has less debt than STOK: ENTX (309K) vs STOK (2.32M). STOK has higher revenues than ENTX: STOK (36.6M) vs ENTX (99K).
ENTXSTOKENTX / STOK
Capitalization91.4M593M15%
EBITDA-9.16M-99.2M9%
Gain YTD-13.443-14.50693%
P/E RatioN/A13.24-
Revenue99K36.6M0%
Total Cash6.92M217M3%
Total Debt309K2.32M13%
FUNDAMENTALS RATINGS
ENTX vs STOK: Fundamental Ratings
ENTX
STOK
OUTLOOK RATING
1..100
420
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6462
P/E GROWTH RATING
1..100
10055
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (50) in the null industry is in the same range as ENTX (71) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to ENTX’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as ENTX (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to ENTX’s over the last 12 months.

STOK's SMR Rating (97) in the null industry is in the same range as ENTX (99) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to ENTX’s over the last 12 months.

STOK's Price Growth Rating (62) in the null industry is in the same range as ENTX (64) in the Pharmaceuticals Major industry. This means that STOK’s stock grew similarly to ENTX’s over the last 12 months.

STOK's P/E Growth Rating (55) in the null industry is somewhat better than the same rating for ENTX (100) in the Pharmaceuticals Major industry. This means that STOK’s stock grew somewhat faster than ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTXSTOK
RSI
ODDS (%)
Bearish Trend 12 days ago
81%
Bearish Trend 12 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 12 days ago
83%
Bearish Trend 12 days ago
84%
Momentum
ODDS (%)
Bearish Trend 12 days ago
89%
Bullish Trend 12 days ago
82%
MACD
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 12 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
88%
Bearish Trend 12 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
86%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
80%
Bullish Trend 20 days ago
84%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 13 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 12 days ago
81%
N/A
Aroon
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 12 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ENTX and

Correlation & Price change

A.I.dvisor tells us that ENTX and ORKA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and ORKA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
-1.34%
ORKA - ENTX
29%
Poorly correlated
+0.26%
CDXS - ENTX
28%
Poorly correlated
-8.63%
KOD - ENTX
28%
Poorly correlated
-2.23%
CVAC - ENTX
28%
Poorly correlated
+2.07%
STOK - ENTX
28%
Poorly correlated
+2.72%
More